This case study analyzes the research and innovation ecosystem at Johns Hopkins University, More about the author examining how the institution has successfully operationalized the “making in English” concept—translating fundamental scientific discoveries into tangible commercial and clinical applications. The analysis reveals that Johns Hopkins has constructed a comprehensive infrastructure spanning from early-stage research funding to venture development, underpinned by a distinctive “business of health ecosystem” that integrates its world-class medical, engineering, and business schools . The university’s approach demonstrates that effective innovation translation requires not merely technological capability but deliberate institutional architecture designed to bridge disciplinary silos, support entrepreneurial talent, and attract external partnerships.
1. Introduction: The Imperative of Translation
Since its founding in 1876, Johns Hopkins University has embodied the principle that research and teaching are inseparable missions . Under its first president, Daniel Coit Gilman, the university revolutionized American higher education by positioning systematic inquiry at the core of its institutional identity. However, in the contemporary landscape, fundamental research alone no longer suffices. The measure of a research university’s impact increasingly depends on its ability to translate discoveries from laboratory benches into patient bedsides, commercial products, and public policy interventions.
The challenge of “making in English”—transforming specialized knowledge into accessible, applicable innovations—has become a defining characteristic of twenty-first century research universities. Johns Hopkins presents a particularly instructive case because it operates at multiple translational interfaces: between medicine and engineering, between academia and industry, and between federal research funding and commercial enterprise. This case study examines how the university has constructed an ecosystem capable of navigating these interfaces effectively.
2. The Institutional Architecture of Innovation
The establishment of Johns Hopkins Technology Ventures (JHTV) in 2013 marked a strategic inflection point in the university’s approach to commercialization . Prior to JHTV’s creation, Johns Hopkins generated substantial intellectual property through its research enterprise—ranking among national leaders in patent grants and federally funded research—but lacked the infrastructure to systematically transform discoveries into viable companies. Christy Wyskiel, an investor and entrepreneur who identified this gap, successfully pitched a vision to university leadership: build formal support systems to remove barriers and connect the entrepreneurial “wisps of an ecosystem” scattered across nine schools .
The results of this infrastructure investment have been substantial. JHTV’s portfolio now encompasses 131 startups that have raised $4.8 billion in capital, generating 45 company exits . The portfolio includes 314 active products, 330 products in development, and 3,805 patents. In fiscal year 2025, 97 licensing agreements generated $59 million in revenue . These metrics demonstrate that deliberate institutional architecture—space, resources, funding, and connective tissue between silos—can accelerate the translation of research into economic and social value.
The physical manifestation of this commitment is the Pava Center (formerly FastForward U), which opened in 2018 as the nexus for student entrepreneurship. The center serves “anyone, from the curious to the committed,” offering a spectrum of programming from the Spark accelerator for early-stage ideas to the Fuel accelerator for ventures seeking to scale . The President’s Venture Fellowship provides two student teams with $140,000 each plus partial Carey Business School scholarships—a signal that entrepreneurship has become institutionally legitimated as a pathway for talented students.
3. The Business of Health Ecosystem
Johns Hopkins’s distinctive competitive advantage lies in what university leaders term the “business of health ecosystem”—the integration of the Carey Business School, School of Medicine, and Whiting School of Engineering . This ecosystem creates opportunities for collaboration that few institutions can replicate.
The AstraZeneca National Healthcare Case Competition provides a concrete illustration of this ecosystem in operation. In November 2025, a team of graduate students from all three schools—dubbed “The Care Continuum”—won the competition by developing a rollout strategy for a new breast cancer therapy . The team’s composition reflected the ecosystem’s strength: medical and PhD students contributed scientific depth about oncology and second-line treatments, while MBA students brought commercial acumen and strategic thinking about physician adoption barriers. As team member Vania Wang, a cellular and molecular medicine PhD candidate, observed, “Just having all of these different perspectives, and ambitious people working really hard on something that we all cared about, that was just a really amazing experience” .
The value flows both directions. AstraZeneca innovation lead Kevin Diehn noted that partnering with Carey yields “a really diverse set of perspectives from medical folks, MBAs, public health. If we can crowdsource ideas from a broad set of really smart people like that, that’s going to set us up for success” . explanation The case competition thus functions as a mechanism for industry partners to access top talent and fresh thinking while providing students with exposure to real-world commercial challenges.
4. AI as a Translational Bridge
Across Johns Hopkins, artificial intelligence has emerged as a critical tool for accelerating translation across multiple domains. The university has positioned AI not merely as a technical field but as a bridge connecting disciplines and enabling new forms of research and application .
At the Applied Physics Laboratory (APL), researchers are exploring how AI can enhance brain-computer interfaces. While the field has historically focused on restoring lost function—enabling paralyzed individuals to control robotic prosthetics through neural signals—APL researchers now envision “augmenting function” by integrating AI directly into neural circuitry . Mike Wolmetz, program manager for frontier intelligence systems at APL, imagines a future where AI assists with name-face recognition by interfacing with specific brain regions. This work exemplifies translation that extends beyond therapeutic restoration into human capability enhancement.
In materials science, K.T. Ramesh’s laboratory has deployed AI and automation to accelerate materials testing by a factor of 1,000 while reducing costs a hundredfold . By generating massive datasets and using machine learning to extract insights, Ramesh’s team has transformed the design process from a reactive question—”What do I have?”—to a proactive one: “What do I want?” This capability has profound implications for designing spacecraft skins capable of withstanding atmospheric re-entry and protective materials for soldiers operating in extreme environments.
The medical applications of AI translation are equally striking. The surgical robot SRTIH, developed through collaboration between the School of Medicine and Whiting School of Engineering, demonstrated in 2025 the ability to autonomously perform soft tissue surgery in porcine models . While previous surgical robots required remote operation by human surgeons, SRTIH adapts to complex environments and executes complete surgical tasks with 100 percent precision. Project leader Axel Krieger compares the breakthrough to autonomous driving: the robot can “operate in multiple conditions and respond flexibly to unexpected situations” .
5. Open Science and Commercial Translation
The relationship between academic research and commercial application at Johns Hopkins reveals a sophisticated understanding of how value flows between sectors. Jean Fan’s JEFworks lab at the Whiting School of Medicine develops open-source computational tools that analyze gene activity at single-cell resolution . These tools are freely shared with the scientific community, enabling researchers worldwide to study diseases from acute kidney injury to brain cancer at unprecedented molecular resolution.
The commercial value generated by this open approach is substantial but indirect. Companies frequently incorporate university-developed open-source software into their own commercial products, creating downstream economic value while accelerating the pace of discovery across the entire biotechnology sector . Fan’s STalign software, which simplifies spatial gene profile alignment, has been integrated into the LatchBio platform for genomic research.
Equally important, university labs provide independent validation of commercial technologies. When companies like 10X Genomics develop new gene-mapping technologies, academic researchers test their accuracy and reliability free from commercial pressures. Fan emphasizes that “because university studies are funded by independent federal grants, rather than by the companies themselves, we can offer unbiased oversight, free from any financial or commercial pressures” . This validation function ensures that technologies entering clinical use have been rigorously evaluated by disinterested experts.
The vulnerability of this ecosystem to federal funding cuts, however, poses significant risks. Fan notes that sweeping NIH funding reductions threaten the training of graduate students and postdoctoral fellows who constitute the pipeline for future researchers and biotech employees. “This shortage could slow down the development of new treatments for patients,” she warns .
6. Translational Research in Practice: Geriatrics Engineering
The Geriatrics Engineering @Johns Hopkins hub, which opened in July 2025 at the Bayview Medical Campus, exemplifies the university’s approach to translational research . The 10,000-square-foot facility, believed to be the first of its kind nationally, brings together faculty and students from engineering, medicine, nursing, public health, and business to develop technology-driven solutions for older adults.
What distinguishes this initiative is its methodological commitment to user-centered design. The hub includes a model apartment—complete with living room, kitchen, bedroom, and bathroom—where older adults and caregivers can test wearable trackers, robotic assistants, and voice-activated systems in a realistic environment . As geriatrician Peter Abadir explains, “So much technology currently on the market is developed by testing it on young people, then reverse-engineered for older adults, and it’s developed in a sterile, studio-like setting. Here we are starting with older adults and determining their needs” .
The research portfolio spans multiple translational pathways. Motion capture technology tracks gait patterns to identify fall risks. Digitized notepads with eye-tracking sensors detect early signs of neurodegenerative disease through changes in reading and handwriting. The InWave headset monitors brain activity and delivers AI-personalized sound patterns to improve sleep quality . Each project aims to produce not merely publications but scalable solutions that can be commercialized and deployed in homes, senior centers, and clinics.
Crucially, Carey Business School faculty and students participate actively in these projects, ensuring that product development incorporates commercial viability considerations from the outset . This integration of business perspective into the earliest stages of technology development distinguishes the Hopkins approach from purely academic research initiatives.
7. The Translational Tissue Engineering Center: A Model for Discipline-Based Translation
The Translational Tissue Engineering Center (TTEC) offers another window into Johns Hopkins’s translational methodology. Organized around three sequential phases—Discovery, Innovation, and Translation—TTEC explicitly structures its research enterprise to move from fundamental understanding to clinical application .
In the Discovery phase, researchers investigate basic biological principles, including cell behavior, instructive materials, and the signals that control tissue development. Computational modeling integrates experimental data across scales, from molecular interactions to whole-organism responses. The Innovation phase translates these discoveries into technologies: therapeutic molecular biotechnologies, biomanufacturing capabilities, and immunoengineering platforms that modulate immune responses for applications ranging from transplant tolerance to cancer treatment .
The Translation phase brings these innovations into clinical testing and implementation. Faculty work across tissue regeneration, cancer therapy, precision medicine, transplantation, and autoimmune diseases, with clinicians and engineers collaborating to design therapies that address real patient needs. This structured approach—moving deliberately from discovery through innovation to translation—provides a template for how research universities can organize themselves to maximize clinical impact.
8. Conclusion: Implications for Research Universities
The Johns Hopkins case yields several insights for institutions seeking to enhance their translational capacity. First, translation requires dedicated infrastructure. The creation of Johns Hopkins Technology Ventures and the Pava Center provided physical space, funding mechanisms, and connective tissue that transformed isolated entrepreneurial efforts into a coherent ecosystem . Institutions cannot rely on serendipity to connect researchers with commercial partners or investors.
Second, interdisciplinary integration must be intentional. The “business of health ecosystem” at Johns Hopkins succeeds because it creates structured opportunities for collaboration across medicine, engineering, and business . Case competitions, joint appointments, and shared research facilities ensure that disciplinary expertise combines around common problems rather than remaining siloed.
Third, translation encompasses multiple pathways. Open-source software development, independent technology validation, startup formation, and corporate partnership all represent legitimate routes to impact . Institutions should support diverse models rather than privileging any single approach.
Fourth, user engagement must occur early and continuously. The Geriatrics Engineering hub’s model apartment methodology—bringing older adults into the design process from the beginning—embodies a principle applicable across translational domains: solutions developed without user input rarely solve user problems .
Finally, the federal research funding ecosystem remains foundational. The translational enterprise at Johns Hopkins depends on NIH and NSF support for training the next generation of researchers and conducting the fundamental science that underlies commercial applications . Threats to this funding represent threats to the entire translational pipeline.
As Christy Wyskiel observed at the 2025 Innovation Summit, JHTV serves as “a front door for campus innovators and external partnerships alike, ensuring productive collaboration between Johns Hopkins, the government, and industry—a tripartite alliance that leverages the strengths of each sector to save lives” . This tripartite model, carefully cultivated over a decade of deliberate investment, Check Out Your URL offers a compelling template for how research universities can fulfill their mission of translating knowledge into impact.
